circRNA basic information
circBase ID: hsa_circ_0001658
Name: -
Synonym: circ_0001658
Host Gene: -
Genomic location(hg19): chr6:157357968-157406039:+
Genomic location(hg38): chr6:157036834-157084905:+
Subcellular localization: not tested
 
 
 
 
 
 
 
Disease basic information
MONDO ID:
0005233
MONDO name: non-small cell lung carcinoma
Disease details: non-small cell lung cancer / NSCLC
Disease DO ID:
3908
Disease MeSH ID:
D002289
Disease NCIt ID:
C2926
Disease ICD11 ID:
-
Disease OMIM ID:
-
Species: Human
Species details: Homo sapiens
Tissue specimen:

NSCLC tissues; adjacent tissues; cancer tissues; corresponding tissues adjacent to tumor

Cell lines:

HEB; H1650; H1650/gefitinib; HCC827; HCC827/gefitinib

In vivo animal model:

-

circRNA-disease information
Expression pattern:
UP
Associated gene: TWIST1 mRNA, TWIST1
Associated microRNA: miR-409-3p
Biological function: Promotes malignant phenotypes and gefitinib resistance of NSCLC cells; knockdown restrains cell viability, reduces proliferation, promotes apoptosis, and lowers gefitinib IC50.
Molecular mechanism: circ_0001658 acts through a ceRNA-like mechanism by directly targeting miR-409-3p, negatively modulating miR-409-3p, and indirectly up-regulating TWIST1 expression to enhance gefitinib resistance.
Biological pathway or process:

proliferation (promotes); apoptosis (inhibits); drug resistance (promotes); ceRNA regulation (other)

Detected method:
Q
M
Validation methods:

RT-qPCR; Microarray; Clinical Sample Validation; Transfection; CCK8; BrdU; Annexin V/PI Flow Cytometry; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); Western Blot; Bioinformatics Analysis

Clinical significance:

High circ_0001658 expression is associated with TNM stage and differentiation degree of NSCLC tissues and adverse pathological characteristics.

Description:

circ_0001658 is up-regulated in NSCLC tissues and gefitinib-resistant NSCLC cells. It promotes NSCLC malignant phenotypes and gefitinib resistance by sponging miR-409-3p and increasing TWIST1 expression; its knockdown reduces gefitinib IC50, suppresses proliferation, and promotes apoptosis.

Confidence score:

0.7283

Other information
Title:

Circ_0001658 regulates gefitinib resistance of non-small cell lung cancer through miR-409-3p/TWIST1 axis.

Journal: Anti-cancer drugs
Published: 2022
PubMed ID: 34694278
Study type:

combined biological and clinical study

Data availability: GSE158695; Supplemental digital content 1, http://links.lww.com/ACD/A421; available from the corresponding author upon request
Code availability: -